"Ofloxacin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
| Descriptor ID |
D015242
|
| MeSH Number(s) |
D03.633.100.810.835.322.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ofloxacin".
Below are MeSH descriptors whose meaning is more specific than "Ofloxacin".
This graph shows the total number of publications written about "Ofloxacin" by people in this website by year, and whether "Ofloxacin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 2 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ofloxacin" by people in Profiles.
-
Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit JS, Dudley MN. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother. 2011 Jun; 55(6):2636-40.
-
Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011 Jun 01; 183(11):1510-6.
-
Hibbard ML, Kopelman TR, O'Neill PJ, Maly TJ, Matthews MR, Cox JC, Vail SJ, Quan AN, Drachman DA. Empiric, broad-spectrum antibiotic therapy with an aggressive de-escalation strategy does not induce gram-negative pathogen resistance in ventilator-associated pneumonia. Surg Infect (Larchmt). 2010 Oct; 11(5):427-32.
-
Szklo A, Mello FC, Guerra RL, Dorman SE, Muzy-de-Souza GR, Conde MB. Alternative anti-tuberculosis regimen including ofloxacin for the treatment of patients with hepatic injury. Int J Tuberc Lung Dis. 2007 Jul; 11(7):775-80.
-
Solomon R, Donnenfeld ED, Perry HD, Rubinfeld RS, Ehrenhaus M, Wittpenn JR, Solomon KD, Manche EE, Moshirfar M, Matzkin DC, Mozayeni RM, Maloney RK. Methicillin-resistant Staphylococcus aureus infectious keratitis following refractive surgery. Am J Ophthalmol. 2007 Apr; 143(4):629-34.
-
Wang S, Rizvi AA. Levofloxacin-induced hypoglycemia in a nondiabetic patient. Am J Med Sci. 2006 Jun; 331(6):334-5.
-
Bosso JA, Mauldin PD. Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2006 Jun; 50(6):2106-12.
-
Cahill JB, Bailey EM, Chien S, Johnson GM. Levofloxacin secretion in breast milk: a case report. Pharmacotherapy. 2005 Jan; 25(1):116-8.
-
Ginsburg AS, Woolwine SC, Hooper N, Benjamin WH, Bishai WR, Dorman SE, Sterling TR. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med. 2003 Nov 13; 349(20):1977-8.
-
Enzweiler KA, Bosso JA, White RL. A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function. Pharmacotherapy. 2003 Jul; 23(7):925-32.